Breast Cancer Survival: Femara Better Than Tamoxifen
Study Shows Breast Cancer Less Likely to Return in Patients Who Take Femara
Tamoxifen Side Effects
Tamoxifen is still widely used in the treatment of younger breast cancer patients, and it is the only drug approved to treat ductal carcinoma in situ (DCIS) -- early breast cancer that has not spread beyond the milk ducts.
Side effects of tamoxifen can include blood clots and an increased risk for endometrial cancer, while potential side effects with aromatase inhibitors include bone loss, an increased risk for heart disease, and joint pain.
Breast cancer specialist Jane Carleton, MD, of the North Shore-LIJ Health System Monter Cancer Center in New York, says between 30% and 50% of patients who take an aromatase inhibitor experience joint pain.
"This is a very common side effect," she tells WebMD.